Basic Information
LncRNA/CircRNA Name | RP11-175D17.3. |
Synonyms | NA |
Region | NA |
Ensemble | NA |
Refseq | NA |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | multiple myeloma |
ICD-0-3 | C42.1 |
Methods | Microarray, qPCR |
Sample | bone marrow |
Expression Pattern | up-regulated |
Function Description | the lncRNA ST3GAL6-AS1, ZNF663P, LAMA5-AS1 and RP11-175D17.3 were significantly upregulated in newly diagnosed MM and R/R MM samples compared with IDA controls and MM patients who got CR (P < 0.05) (Fig. 6). There was no significant differences between newly diagnosed MM patients and R/R ones, or MM patients who received CR and IDA controls (P > 0.05)(Fig. 6). the expression level of ST3GAL6-AS1 was associated with D-S (P = 0.021), ISS (P = 0.038), R-ISS stage (P = 0.027), mSMART risk status (P = 0.013) and the percentage of malignant plasma cells in bone marrow (P = 0.031). |
Pubmed ID | 29459023 |
Year | 2018 |
Title | Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma. |
External Links
Links for RP11-175D17.3. | GenBank HGNC NONCODE |
Links for multiple myeloma | OMIM COSMIC |